- Home
- WNW vs BIAF Comparison
WNW vs BIAF Comparison
Compare WNW & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WNW | BIAF |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | China | United States |
| Employees | N/A | 57 |
| Industry | Catalog/Specialty Distribution | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3M | 4.6M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | WNW | BIAF |
|---|---|---|
| Price | $3.58 | $0.83 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 189.1K | ★ 412.3K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $20.95 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.14 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.05 | $0.23 |
| 52 Week High | $13.52 | $13.50 |
Technical Indicators
Market Signals| Indicator | WNW | BIAF |
|---|---|---|
| Relative Strength Index (RSI) | 51.82 | 27.67 |
| Support Level | $2.95 | $0.74 |
| Resistance Level | $4.67 | $1.45 |
| Average True Range (ATR) | 0.34 | 0.10 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 33.60 | 5.62 |
Price Performance
Historical ComparisonAbout WNW Meiwu Technology Company Limited
Meiwu Technology Co Ltd operates as an online food retail store and franchise restaurants in China. The products offered include green food, organic food, intangible cultural heritage food products, agricultural products bearing geographical indications, and pollution-free products. It operates in three segments including Clean Food platform, Skincare products & service and Technical Service. The company generates the majority of its revenue from Technical services.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.